Candesartan cilexetil: a review of its use in the management of chronic heart failure.
Candesartan cilexetil is the orally administered pro-drug of candesartan, a highly selective antagonist of the angiotensin II subtype 1 receptor that mediates the pressor activities of angiotensin II. Candesartan cilexetil is widely used for the treatment of hypertension and has recently been approved in Europe for the treatment of chronic heart failure (CHF) in patients with impaired left ventricular (LV) systolic function. Results of the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) programme suggest that oral candesartan cilexetil reduces morbidity and mortality in patients with CHF and LV ejection fraction (LVEF) < or =40%. There are cardiovascular benefits when candesartan cilexetil is administered as an alternative to an ACE inhibitor, or as an add-on to current treatment regimens that include an ACE inhibitor, in symptomatic CHF. While tolerability is generally good, renal monitoring is required. The recent approval of candesartan cilexetil as both add-on and alternative therapy to ACE inhibitors in patients with CHF and impaired LV systolic function recognises the cardiovascular benefits of candesartan cilexetil in both types of treatment regimens.
Fenton
Caroline
C
Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland, 1311, New Zealand. demail@adis.co.nz
Scott
Lesley J
LJ
D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D001562:Benzimidazoles / Q000494:pharmacology*; D001713:Biphenyl Compounds / Q000494:pharmacology*; D002908:Chronic Disease; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D013777:Tetrazoles / Q000494:pharmacology*
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C077793:candesartan cilexetil
Heart. 2002 Oct;88 Suppl 2:ii40-6
12213800
Circulation. 2004 Oct 26;110(17):2618-26
15492298
Eur Heart J. 2001 Sep;22(17):1527-60
11492984
N Engl J Med. 2003 Nov 13;349(20):1893-906
14610160
Eur J Heart Fail. 2003 Oct;5(5):669-77
14607207
Can J Cardiol. 1997 Dec;13(12):1166-74
9444298
Ann Intern Med. 2004 Jul 20;141(2):102-12
15262665
Circulation. 1992 Feb;85(2):790-804
1370925
J Am Coll Cardiol. 2004 Nov 2;44(9):1841-6
15519017
Can J Cardiol. 2003 Mar 31;19(4):347-56
12704478
Lancet. 2003 Sep 6;362(9386):777-81
13678871
J Am Coll Cardiol. 2001 Dec;38(7):2101-13
11738322
Drugs. 2002;62(10):1433-40
12093312
Am J Health Syst Pharm. 2004 May 1;61 Suppl 2:S4-13
15160833
J Hum Hypertens. 1997 Sep;11 Suppl 2:S37-42
9331004
Clin Drug Investig. 2003;23(8):545-50
17535067
Clin Pharmacokinet. 2002;41(1):7-17
11825094
N Engl J Med. 1996 Jun 20;334(25):1649-54
8628362
J Hum Hypertens. 2002 Aug;16 Suppl 3:S9-S16
12140723
Drugs. 2002;62(8):1253-87
12010090
Eur Heart J. 2004 Mar;25(5):357-8
15033244
Eur Heart J. 2004 Nov;25(21):1920-6
15522471
Lancet. 2003 Sep 6;362(9386):759-66
13678868
Ethn Dis. 2002 Winter;12(1):S1-3-11
11913616
Lancet. 2003 Jul 5;362(9377):7-13
12853193
Circulation. 2002 Apr 30;105(17):2099-106
11980691
J Hum Hypertens. 1997 Sep;11 Suppl 2:S31-5
9331003
J Am Coll Cardiol. 2002 Jan 2;39(1):79-82
11755290
J Hypertens. 2001 Oct;19(10):1905-12
11593113
Circulation. 1999 Nov 30;100(22):2224-30
10577995
Lancet. 2003 Sep 6;362(9386):767-71
13678869
Drugs. 2002;62(5):787-816
11929332
Circulation. 1999 Sep 7;100(10):1056-64
10477530
Drugs. 1998 Nov;56(5):847-69
9829158
Am Heart J. 2003 Mar;145(3):E14
12660683
Am J Hypertens. 2002 Nov;15(11):1006-14
12441224
J Hum Hypertens. 1997 Sep;11 Suppl 2:S19-25
9331000
Eur J Heart Fail. 2003 Jun;5(3):261-70
12798823
Circulation. 1998 Jul 7;98(1):73-81
9665063
Lancet. 2003 Sep 6;362(9386):772-6
13678870
N Engl J Med. 2001 Dec 6;345(23):1667-75
11759645
Hypertension. 1995 Jan;25(1):14-21
7843746
Eur J Clin Pharmacol. 1999 Feb;54(12):953-8
10192757
Eur Heart J. 2003 Oct;24(19):1727-34
14522567